{ "items": [ "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n DEVELOPMENT OF AN OPTIMAL F/HN PSEUDOTYPED SIV VECTOR FOR CF GENE THERAPY\n

\n \n \n

\n \n Conference paper\n \n

\n \n\n \n \n \n

Hyde SC. et al, (2014), THORAX, 69, A165 - A166

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n IMMUNE RESPONSES TO SINGLE AND REPEATED ADMINISTRATION OF PGM169/GL67A: THE UK CF GENE THERAPY CONSORTIUM CLINICAL TRIALS\n

\n \n \n

\n \n Conference paper\n \n

\n \n\n \n \n \n

Griesenbach U. et al, (2014), THORAX, 69, A166 - A166

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n STANDARDISATION OF LUNG CLEARANCE INDEX IN A MULTICENTRE CLINICAL TRIAL\n

\n \n \n

\n \n Conference paper\n \n

\n \n\n \n \n \n

Armstrong DK. et al, (2014), THORAX, 69, A168 - A169

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n \n
\n \n \n

\n Assessment of immune responses to single and repeat dose aeroslisation of the non-viral formualtion PGM169/GL67A in cystic fibrosis patients\n

\n \n \n

\n \n Conference paper\n \n

\n \n\n \n \n \n

Griesenbach U. et al, (2014), HUMAN GENE THERAPY, 25, A110 - A111

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n \n
\n \n \n

\n Development of F/HN pseudotyped Lentivirus for airway gene transfer\n

\n \n \n

\n \n Conference paper\n \n

\n \n\n \n \n \n

Gill DR. et al, (2014), HUMAN GENE THERAPY, 25, A43 - A43

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n \n
\n \n \n

\n Results of a Phase IIb non-viral gene therapy trial from the UK CF Gene Therapy Consortium\n

\n \n \n

\n \n Conference paper\n \n

\n \n\n \n \n \n

Griesenbach U. et al, (2014), HUMAN GENE THERAPY, 25, A51 - A51

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Delivery of genes into the CF airway.\n

\n \n \n

\n \n Journal article\n \n

\n \n\n \n \n \n

Gill DR. and Hyde SC., (2014), Thorax, 69, 962 - 964

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Effects of a novel archaeal tetraether-based colipid on the in vivo gene transfer activity of two cationic amphiphiles.\n

\n \n \n

\n \n Journal article\n \n

\n \n\n \n \n \n

Le Gall T. et al, (2014), Mol Pharm, 11, 2973 - 2988

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n \n
\n \n \n

\n CARDIOPULMONARY EXERCISE TESTING (CPET) AS AN OUTCOME MEASURE IN CYSTIC FIBROSIS CLINICAL TRIAL\n

\n \n \n

\n \n Conference paper\n \n

\n \n\n \n \n \n

Elgmati HI. et al, (2014), PEDIATRIC PULMONOLOGY, 49, 366 - 366

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n \n
\n \n \n

\n IMMUNE RESPONSES TO SINGLE AND REPEATED ADMINISTRATION OF PGM169/GL67A: THE UK CF GENE THERAPY CONSORTIUM CLINICAL TRIALS\n

\n \n \n

\n \n Conference paper\n \n

\n \n\n \n \n \n

Griesenbach U. et al, (2014), PEDIATRIC PULMONOLOGY, 49, 297 - 297

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n \n
\n \n \n

\n LARGE-SCALE PRODUCTION OF LENTIVIRAL VECTORS FOR CF LUNG GENE THERAPY\n

\n \n \n

\n \n Conference paper\n \n

\n \n\n \n \n \n

Davies LA. et al, (2014), PEDIATRIC PULMONOLOGY, 49, 293 - 293

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n \n
\n \n \n

\n LUNG FUNCTION OUTCOME MEASURES IN A MULTIDOSE TRIAL OF NON-VIRAL GENE THERAPY IN PATIENTS WITH CF\n

\n \n \n

\n \n Conference paper\n \n

\n \n\n \n \n \n

Bayfield KJ. et al, (2014), PEDIATRIC PULMONOLOGY, 49, 364 - 365

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n \n
\n \n \n

\n MOLECULAR ANALYSES OF VECTOR DELIVERY AND GENE EXPRESSION IN A MULTIDOSE TRIAL OF NON-VIRAL GENE THERAPY IN PATIENTS WITH CF\n

\n \n \n

\n \n Conference paper\n \n

\n \n\n \n \n \n

Sumner-Jones SG. et al, (2014), PEDIATRIC PULMONOLOGY, 49, 302 - 302

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Delivery of genes into the CF airway\n

\n \n \n

\n \n Journal article\n \n

\n \n\n \n \n \n

Gill DR. et al, (2014), Thorax

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Aerosol delivery of DNA/liposomes to the lung for cystic fibrosis gene therapy.\n

\n \n \n

\n \n Journal article\n \n

\n \n\n \n \n \n

Davies LA. et al, (2014), Hum Gene Ther Clin Dev, 25, 97 - 107

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n \n
\n \n \n

\n A phase IIb Double-Blind Placebo-Controlled Trial of Non-Viral Gene Transfer for Cystic Fibrosis\n

\n \n \n

\n \n Conference paper\n \n

\n \n\n \n \n \n

Pringle IA. et al, (2014), MOLECULAR THERAPY, 22, S229 - S230

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n \n
\n \n \n

\n Alpha-1-antitrypsin gene therapy for lung disease\n

\n \n \n

\n \n Conference paper\n \n

\n \n\n \n \n \n

Paul-Smith M. et al, (2014), HUMAN GENE THERAPY, 25, A15 - A15

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n \n
\n \n \n

\n Gene therapy: barriers to translation\n

\n \n \n

\n \n Conference paper\n \n

\n \n\n \n \n \n

Davie N. et al, (2014), HUMAN GENE THERAPY, 25, A12 - A12

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Aerosol delivery of DNA/liposomes to the lung for cystic fibrosis gene therapy.\n

\n \n \n

\n \n Journal article\n \n

\n \n\n \n \n \n

Davies LA. et al, (2014), Hum Gene Ther Clin Dev

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n \n
\n \n \n

\n Clinical Development of an Optimal F/HN Pseudotyped SIV Vector for Cystic Fibrosis Lung Gene Therapy\n

\n \n \n

\n \n Conference paper\n \n

\n \n\n \n \n \n

Pringle IA. et al, (2014), MOLECULAR THERAPY, 22, S141 - S141

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n" ], "more": "\n\n \n \n Load More\n \n \n\n", "msg": "" }